Rifalazil

DB04934InvestigationalSmall molecule

Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

Mechanism: The potent antimycobacterial activity of rifalazil is due to inhibition of bacterial RNA polymerase.
Curator reviewed
Primary indication: Investigated for use/treatment in atherosclerosis, bacterial infection, and peripheral vascular disease.Curator reviewed
Formula / weight: C₅₁H₆₄N₄O₁₃ · 941.088 g/mol (avg)
Code names: ABI 1648 · KRM-1648

Resolves to

Compound

UNIIS1976TE8QKCAS129791-92-0ChEMBLCHEMBL236297PubChem6540558KEGGD02550

Structure

InChIKeyUEFHFKKWYKVLDC-HTQYORAHSA-NSMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1OC5=CC(=CC(O)=C5N=C1C4=C3C2=O)N1CCN(CC(C)C)CC1

Targets

P0A8V2rpoB

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

165Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rifalazil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account